Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks™ HT

This publication has 41 references indexed in Scilit:

• THE BINDING OF DRUGS TO HEPATOCYTES AND ITS RELATIONSHIP TO PHYSICOCHEMICAL PROPERTIES
  Drug Metabolism and Disposition, 2005
• Predictive in silico modeling for hERG channel blockers
  Drug Discovery Today, 2005
• Potent N-(1,3-Thiazol-2-yl)pyridin-2-amine Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors with Excellent Pharmacokinetics and Low Affinity for the hERG Ion Channel
  Journal of Medicinal Chemistry, 2004
• A model for identifying HERG K+ channel blockers
  Bioorganic & Medicinal Chemistry, 2004
• Validation of a [3H]Astemizole Binding Assay in HEK293 Cells Expressing HERG K+ Channels
  Journal of Pharmacological Sciences, 2004
• A radiolabeled peptide ligand of the hERG channel, [ 125 I]-BeKm-1
  Pflügers Archiv - European Journal of Physiology, 2003
• The Influence of Nonspecific Microsomal Binding on Apparent Intrinsic Clearance, and Its Prediction from Physicochemical Properties
  Drug Metabolism and Disposition, 2002
• Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels
  Proceedings of the National Academy of Sciences, 2002
• Toward a Pharmacophore for Drugs Inducing the Long QT Syndrome: Insights from a CoMFA Study of HERG K⁺ Channel Blockers
  Journal of Medicinal Chemistry, 2002
• Design and Biological Activity of (S)-4-(5-{[1-(3-Chlorobenzyl)-2- oxopyrrolidin-3-ylamino]methyl}imidazol-1-ylmethyl)benzonitrile, a 3-Aminopyrrolidinone Farnesyltransferase Inhibitor with Excellent Cell Potency
  Journal of Medicinal Chemistry, 2001